Following a resubmission.
Rotigotine (Neupro®) is accepted for use within NHS Scotland for the treatment of the signs and symptoms of early-stage idiopathic Parkinson’s disease as monotherapy (i.e. without levodopa).
Rotigotine was superior to placebo in two randomised controlled trials. However, in one active comparator study it was less effective than a non-ergolinic dopamine agonist comparator. Rotigotine transdermal patch offers an alternative non-ergolinic dopamine agonist at a lower cost in a formulation that does not have to be taken by mouth.
Download detailed advice83KB (PDF)
- Medicine name:
- rotigotine 2mg/24 hours, 4mg/24 hours, 6mg/24 hours, 8mg/24 hours transdermal patch (Neupro)
- SMC ID:
- Early-stage Parkinson's disease
- Pharmaceutical company
- Schwarz Pharma Ltd
- BNF chapter
- Central nervous system
- Submission type
- Date advice published
- 09 July 2007